Research ArticleArticle
Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment
D. James Haddon, Hannah E. Wand, Justin A. Jarrell, Robert F. Spiera, Paul J. Utz, Jessica K. Gordon and Lorinda S. Chung
The Journal of Rheumatology March 2017, jrheum.160833; DOI: https://doi.org/10.3899/jrheum.160833
D. James Haddon
From the Division of Immunology and Rheumatology, Stanford University School of Medicine; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford; Department of Rheumatology, Palo Alto VA Health Care System, Palo Alto, California; Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA. Supported by Novartis (investigator-initiated grant), the Rudolph Rupert Scleroderma Program at the Hospital for Special Surgery, the Donald E. and Delia B. Baxter Foundation (Career Development Award to PJU), the Floren Family Trust (gift to PJU), the Ben May Charitable Trust (gift to PJU), the National Heart Lung and Blood Institute (Proteomics Contract 268201000034C to PJU), the National Institutes of Health (grant numbers T32GM007365, U19-AI082719, U19-AI110491, UH2-AR067676, UM2- AR067678, UM1-AI110498, and U19-AI090019 all to PJU), the Alliance for Lupus Research (grant number 21858 to PJU), the Canadian Institutes for Health Research (Fellowship to DJH), the Stanford Translational Research and Applied Medicine Program (Pilot Grant to DJH), the Scleroderma Research Foundation (to LSC), the Scleroderma Foundation (to LSC and New Investigator Grant to JKG), the Scleroderma Clinical Trials Consortium (to LSC), the Hospital for Special Surgery/Kellen Family Foundation (Clinician Scientist Development Award to JKG), and the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (5U19AI056363-10 to RFS). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 261382. D.J. Haddon, PhD, Research Associate, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; H.E. Wand, BS, Genetic Counseling Candidate, Division of Immunology and Rheumatology, Stanford University School of Medicine; J.A. Jarrell, PhD Candidate, Immunology, Division of Immunology and Rheumatology, Stanford University School of Medicine; R.F. Spiera, MD, Professor of Clinical Medicine, Rheumatology and Director, Vasculitis and Scleroderma Program, Department of Rheumatology, Hospital for Special Surgery; P.J. Utz, MD, Professor of Medicine, Immunology and Rheumatology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine; J.K. Gordon, MD, Assistant Professor of Medicine, Rheumatology, Department of Rheumatology, Hospital for Special Surgery, New York; L.S. Chung, MD, MS, Associate Professor of Medicine, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine, and Department of Rheumatology, Palo Alto VA Health Care System. D.J. Haddon and H.E. Wand contributed equally to the manuscript. Drs. J.K. Gordon and L.S. Chung also contributed equally to the manuscript. Address correspondence to Dr. L.S. Chung, Stanford University School of Medicine, Immunology and Rheumatology, 3801 Miranda Ave., Rm B2-139, Palo Alto VA Hospital, Palo Alto, California 94304, USA. E-mail: shauwei@stanford.edu. Accepted for publication January 25, 2017.
Hannah E. Wand
From the Division of Immunology and Rheumatology, Stanford University School of Medicine; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford; Department of Rheumatology, Palo Alto VA Health Care System, Palo Alto, California; Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA. Supported by Novartis (investigator-initiated grant), the Rudolph Rupert Scleroderma Program at the Hospital for Special Surgery, the Donald E. and Delia B. Baxter Foundation (Career Development Award to PJU), the Floren Family Trust (gift to PJU), the Ben May Charitable Trust (gift to PJU), the National Heart Lung and Blood Institute (Proteomics Contract 268201000034C to PJU), the National Institutes of Health (grant numbers T32GM007365, U19-AI082719, U19-AI110491, UH2-AR067676, UM2- AR067678, UM1-AI110498, and U19-AI090019 all to PJU), the Alliance for Lupus Research (grant number 21858 to PJU), the Canadian Institutes for Health Research (Fellowship to DJH), the Stanford Translational Research and Applied Medicine Program (Pilot Grant to DJH), the Scleroderma Research Foundation (to LSC), the Scleroderma Foundation (to LSC and New Investigator Grant to JKG), the Scleroderma Clinical Trials Consortium (to LSC), the Hospital for Special Surgery/Kellen Family Foundation (Clinician Scientist Development Award to JKG), and the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (5U19AI056363-10 to RFS). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 261382. D.J. Haddon, PhD, Research Associate, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; H.E. Wand, BS, Genetic Counseling Candidate, Division of Immunology and Rheumatology, Stanford University School of Medicine; J.A. Jarrell, PhD Candidate, Immunology, Division of Immunology and Rheumatology, Stanford University School of Medicine; R.F. Spiera, MD, Professor of Clinical Medicine, Rheumatology and Director, Vasculitis and Scleroderma Program, Department of Rheumatology, Hospital for Special Surgery; P.J. Utz, MD, Professor of Medicine, Immunology and Rheumatology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine; J.K. Gordon, MD, Assistant Professor of Medicine, Rheumatology, Department of Rheumatology, Hospital for Special Surgery, New York; L.S. Chung, MD, MS, Associate Professor of Medicine, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine, and Department of Rheumatology, Palo Alto VA Health Care System. D.J. Haddon and H.E. Wand contributed equally to the manuscript. Drs. J.K. Gordon and L.S. Chung also contributed equally to the manuscript. Address correspondence to Dr. L.S. Chung, Stanford University School of Medicine, Immunology and Rheumatology, 3801 Miranda Ave., Rm B2-139, Palo Alto VA Hospital, Palo Alto, California 94304, USA. E-mail: shauwei@stanford.edu. Accepted for publication January 25, 2017.
Justin A. Jarrell
From the Division of Immunology and Rheumatology, Stanford University School of Medicine; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford; Department of Rheumatology, Palo Alto VA Health Care System, Palo Alto, California; Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA. Supported by Novartis (investigator-initiated grant), the Rudolph Rupert Scleroderma Program at the Hospital for Special Surgery, the Donald E. and Delia B. Baxter Foundation (Career Development Award to PJU), the Floren Family Trust (gift to PJU), the Ben May Charitable Trust (gift to PJU), the National Heart Lung and Blood Institute (Proteomics Contract 268201000034C to PJU), the National Institutes of Health (grant numbers T32GM007365, U19-AI082719, U19-AI110491, UH2-AR067676, UM2- AR067678, UM1-AI110498, and U19-AI090019 all to PJU), the Alliance for Lupus Research (grant number 21858 to PJU), the Canadian Institutes for Health Research (Fellowship to DJH), the Stanford Translational Research and Applied Medicine Program (Pilot Grant to DJH), the Scleroderma Research Foundation (to LSC), the Scleroderma Foundation (to LSC and New Investigator Grant to JKG), the Scleroderma Clinical Trials Consortium (to LSC), the Hospital for Special Surgery/Kellen Family Foundation (Clinician Scientist Development Award to JKG), and the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (5U19AI056363-10 to RFS). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 261382. D.J. Haddon, PhD, Research Associate, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; H.E. Wand, BS, Genetic Counseling Candidate, Division of Immunology and Rheumatology, Stanford University School of Medicine; J.A. Jarrell, PhD Candidate, Immunology, Division of Immunology and Rheumatology, Stanford University School of Medicine; R.F. Spiera, MD, Professor of Clinical Medicine, Rheumatology and Director, Vasculitis and Scleroderma Program, Department of Rheumatology, Hospital for Special Surgery; P.J. Utz, MD, Professor of Medicine, Immunology and Rheumatology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine; J.K. Gordon, MD, Assistant Professor of Medicine, Rheumatology, Department of Rheumatology, Hospital for Special Surgery, New York; L.S. Chung, MD, MS, Associate Professor of Medicine, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine, and Department of Rheumatology, Palo Alto VA Health Care System. D.J. Haddon and H.E. Wand contributed equally to the manuscript. Drs. J.K. Gordon and L.S. Chung also contributed equally to the manuscript. Address correspondence to Dr. L.S. Chung, Stanford University School of Medicine, Immunology and Rheumatology, 3801 Miranda Ave., Rm B2-139, Palo Alto VA Hospital, Palo Alto, California 94304, USA. E-mail: shauwei@stanford.edu. Accepted for publication January 25, 2017.
Robert F. Spiera
From the Division of Immunology and Rheumatology, Stanford University School of Medicine; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford; Department of Rheumatology, Palo Alto VA Health Care System, Palo Alto, California; Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA. Supported by Novartis (investigator-initiated grant), the Rudolph Rupert Scleroderma Program at the Hospital for Special Surgery, the Donald E. and Delia B. Baxter Foundation (Career Development Award to PJU), the Floren Family Trust (gift to PJU), the Ben May Charitable Trust (gift to PJU), the National Heart Lung and Blood Institute (Proteomics Contract 268201000034C to PJU), the National Institutes of Health (grant numbers T32GM007365, U19-AI082719, U19-AI110491, UH2-AR067676, UM2- AR067678, UM1-AI110498, and U19-AI090019 all to PJU), the Alliance for Lupus Research (grant number 21858 to PJU), the Canadian Institutes for Health Research (Fellowship to DJH), the Stanford Translational Research and Applied Medicine Program (Pilot Grant to DJH), the Scleroderma Research Foundation (to LSC), the Scleroderma Foundation (to LSC and New Investigator Grant to JKG), the Scleroderma Clinical Trials Consortium (to LSC), the Hospital for Special Surgery/Kellen Family Foundation (Clinician Scientist Development Award to JKG), and the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (5U19AI056363-10 to RFS). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 261382. D.J. Haddon, PhD, Research Associate, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; H.E. Wand, BS, Genetic Counseling Candidate, Division of Immunology and Rheumatology, Stanford University School of Medicine; J.A. Jarrell, PhD Candidate, Immunology, Division of Immunology and Rheumatology, Stanford University School of Medicine; R.F. Spiera, MD, Professor of Clinical Medicine, Rheumatology and Director, Vasculitis and Scleroderma Program, Department of Rheumatology, Hospital for Special Surgery; P.J. Utz, MD, Professor of Medicine, Immunology and Rheumatology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine; J.K. Gordon, MD, Assistant Professor of Medicine, Rheumatology, Department of Rheumatology, Hospital for Special Surgery, New York; L.S. Chung, MD, MS, Associate Professor of Medicine, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine, and Department of Rheumatology, Palo Alto VA Health Care System. D.J. Haddon and H.E. Wand contributed equally to the manuscript. Drs. J.K. Gordon and L.S. Chung also contributed equally to the manuscript. Address correspondence to Dr. L.S. Chung, Stanford University School of Medicine, Immunology and Rheumatology, 3801 Miranda Ave., Rm B2-139, Palo Alto VA Hospital, Palo Alto, California 94304, USA. E-mail: shauwei@stanford.edu. Accepted for publication January 25, 2017.
Paul J. Utz
From the Division of Immunology and Rheumatology, Stanford University School of Medicine; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford; Department of Rheumatology, Palo Alto VA Health Care System, Palo Alto, California; Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA. Supported by Novartis (investigator-initiated grant), the Rudolph Rupert Scleroderma Program at the Hospital for Special Surgery, the Donald E. and Delia B. Baxter Foundation (Career Development Award to PJU), the Floren Family Trust (gift to PJU), the Ben May Charitable Trust (gift to PJU), the National Heart Lung and Blood Institute (Proteomics Contract 268201000034C to PJU), the National Institutes of Health (grant numbers T32GM007365, U19-AI082719, U19-AI110491, UH2-AR067676, UM2- AR067678, UM1-AI110498, and U19-AI090019 all to PJU), the Alliance for Lupus Research (grant number 21858 to PJU), the Canadian Institutes for Health Research (Fellowship to DJH), the Stanford Translational Research and Applied Medicine Program (Pilot Grant to DJH), the Scleroderma Research Foundation (to LSC), the Scleroderma Foundation (to LSC and New Investigator Grant to JKG), the Scleroderma Clinical Trials Consortium (to LSC), the Hospital for Special Surgery/Kellen Family Foundation (Clinician Scientist Development Award to JKG), and the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (5U19AI056363-10 to RFS). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 261382. D.J. Haddon, PhD, Research Associate, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; H.E. Wand, BS, Genetic Counseling Candidate, Division of Immunology and Rheumatology, Stanford University School of Medicine; J.A. Jarrell, PhD Candidate, Immunology, Division of Immunology and Rheumatology, Stanford University School of Medicine; R.F. Spiera, MD, Professor of Clinical Medicine, Rheumatology and Director, Vasculitis and Scleroderma Program, Department of Rheumatology, Hospital for Special Surgery; P.J. Utz, MD, Professor of Medicine, Immunology and Rheumatology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine; J.K. Gordon, MD, Assistant Professor of Medicine, Rheumatology, Department of Rheumatology, Hospital for Special Surgery, New York; L.S. Chung, MD, MS, Associate Professor of Medicine, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine, and Department of Rheumatology, Palo Alto VA Health Care System. D.J. Haddon and H.E. Wand contributed equally to the manuscript. Drs. J.K. Gordon and L.S. Chung also contributed equally to the manuscript. Address correspondence to Dr. L.S. Chung, Stanford University School of Medicine, Immunology and Rheumatology, 3801 Miranda Ave., Rm B2-139, Palo Alto VA Hospital, Palo Alto, California 94304, USA. E-mail: shauwei@stanford.edu. Accepted for publication January 25, 2017.
Jessica K. Gordon
From the Division of Immunology and Rheumatology, Stanford University School of Medicine; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford; Department of Rheumatology, Palo Alto VA Health Care System, Palo Alto, California; Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA. Supported by Novartis (investigator-initiated grant), the Rudolph Rupert Scleroderma Program at the Hospital for Special Surgery, the Donald E. and Delia B. Baxter Foundation (Career Development Award to PJU), the Floren Family Trust (gift to PJU), the Ben May Charitable Trust (gift to PJU), the National Heart Lung and Blood Institute (Proteomics Contract 268201000034C to PJU), the National Institutes of Health (grant numbers T32GM007365, U19-AI082719, U19-AI110491, UH2-AR067676, UM2- AR067678, UM1-AI110498, and U19-AI090019 all to PJU), the Alliance for Lupus Research (grant number 21858 to PJU), the Canadian Institutes for Health Research (Fellowship to DJH), the Stanford Translational Research and Applied Medicine Program (Pilot Grant to DJH), the Scleroderma Research Foundation (to LSC), the Scleroderma Foundation (to LSC and New Investigator Grant to JKG), the Scleroderma Clinical Trials Consortium (to LSC), the Hospital for Special Surgery/Kellen Family Foundation (Clinician Scientist Development Award to JKG), and the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (5U19AI056363-10 to RFS). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 261382. D.J. Haddon, PhD, Research Associate, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; H.E. Wand, BS, Genetic Counseling Candidate, Division of Immunology and Rheumatology, Stanford University School of Medicine; J.A. Jarrell, PhD Candidate, Immunology, Division of Immunology and Rheumatology, Stanford University School of Medicine; R.F. Spiera, MD, Professor of Clinical Medicine, Rheumatology and Director, Vasculitis and Scleroderma Program, Department of Rheumatology, Hospital for Special Surgery; P.J. Utz, MD, Professor of Medicine, Immunology and Rheumatology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine; J.K. Gordon, MD, Assistant Professor of Medicine, Rheumatology, Department of Rheumatology, Hospital for Special Surgery, New York; L.S. Chung, MD, MS, Associate Professor of Medicine, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine, and Department of Rheumatology, Palo Alto VA Health Care System. D.J. Haddon and H.E. Wand contributed equally to the manuscript. Drs. J.K. Gordon and L.S. Chung also contributed equally to the manuscript. Address correspondence to Dr. L.S. Chung, Stanford University School of Medicine, Immunology and Rheumatology, 3801 Miranda Ave., Rm B2-139, Palo Alto VA Hospital, Palo Alto, California 94304, USA. E-mail: shauwei@stanford.edu. Accepted for publication January 25, 2017.
Lorinda S. Chung
From the Division of Immunology and Rheumatology, Stanford University School of Medicine; Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford; Department of Rheumatology, Palo Alto VA Health Care System, Palo Alto, California; Department of Rheumatology, Hospital for Special Surgery, New York, New York, USA. Supported by Novartis (investigator-initiated grant), the Rudolph Rupert Scleroderma Program at the Hospital for Special Surgery, the Donald E. and Delia B. Baxter Foundation (Career Development Award to PJU), the Floren Family Trust (gift to PJU), the Ben May Charitable Trust (gift to PJU), the National Heart Lung and Blood Institute (Proteomics Contract 268201000034C to PJU), the National Institutes of Health (grant numbers T32GM007365, U19-AI082719, U19-AI110491, UH2-AR067676, UM2- AR067678, UM1-AI110498, and U19-AI090019 all to PJU), the Alliance for Lupus Research (grant number 21858 to PJU), the Canadian Institutes for Health Research (Fellowship to DJH), the Stanford Translational Research and Applied Medicine Program (Pilot Grant to DJH), the Scleroderma Research Foundation (to LSC), the Scleroderma Foundation (to LSC and New Investigator Grant to JKG), the Scleroderma Clinical Trials Consortium (to LSC), the Hospital for Special Surgery/Kellen Family Foundation (Clinician Scientist Development Award to JKG), and the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (5U19AI056363-10 to RFS). The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 261382. D.J. Haddon, PhD, Research Associate, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine; H.E. Wand, BS, Genetic Counseling Candidate, Division of Immunology and Rheumatology, Stanford University School of Medicine; J.A. Jarrell, PhD Candidate, Immunology, Division of Immunology and Rheumatology, Stanford University School of Medicine; R.F. Spiera, MD, Professor of Clinical Medicine, Rheumatology and Director, Vasculitis and Scleroderma Program, Department of Rheumatology, Hospital for Special Surgery; P.J. Utz, MD, Professor of Medicine, Immunology and Rheumatology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine; J.K. Gordon, MD, Assistant Professor of Medicine, Rheumatology, Department of Rheumatology, Hospital for Special Surgery, New York; L.S. Chung, MD, MS, Associate Professor of Medicine, Immunology and Rheumatology, Division of Immunology and Rheumatology, Stanford University School of Medicine, and Department of Rheumatology, Palo Alto VA Health Care System. D.J. Haddon and H.E. Wand contributed equally to the manuscript. Drs. J.K. Gordon and L.S. Chung also contributed equally to the manuscript. Address correspondence to Dr. L.S. Chung, Stanford University School of Medicine, Immunology and Rheumatology, 3801 Miranda Ave., Rm B2-139, Palo Alto VA Hospital, Palo Alto, California 94304, USA. E-mail: shauwei@stanford.edu. Accepted for publication January 25, 2017.
Article Figures & Data
Additional Files
Data Supplement
Files in this Data Supplement:
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment
D. James Haddon, Hannah E. Wand, Justin A. Jarrell, Robert F. Spiera, Paul J. Utz, Jessica K. Gordon, Lorinda S. Chung
The Journal of Rheumatology Mar 2017, jrheum.160833; DOI: 10.3899/jrheum.160833
Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment
D. James Haddon, Hannah E. Wand, Justin A. Jarrell, Robert F. Spiera, Paul J. Utz, Jessica K. Gordon, Lorinda S. Chung
The Journal of Rheumatology Mar 2017, jrheum.160833; DOI: 10.3899/jrheum.160833